Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey

Genetics in Medicine

Volumn 13, Issue 2, 2011, Pages 102-109

  Muenzer, Joseph ^a   Beck, Michael ^b   Giugliani, Roberto ^c   Suzuki, Yasuyuki ^d   Tylki Szymanska, Anna ^e   Valayannopoulos, Vassili ^f   Vellodi, Ashok ^g   Wraith, James E ^h  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Hunter syndrome; idursulfase; safety

Indexed keywords

CREATININE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

AGITATION; ALLERGIC CONJUNCTIVITIS; ANAPHYLAXIS; ARTICLE; BEHAVIOR DISORDER; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; BRONCHOSPASM; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; COGNITION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ENZYME REPLACEMENT; ERYTHEMA; FACE EDEMA; FATIGUE; FLUSHING; GAIT DISORDER; HUMAN; HUNTER SYNDROME; HYDROCEPHALUS; HYPERACTIVITY; HYPOTENSION; LIVER SIZE; MACULOPAPULAR RASH; OUTCOME ASSESSMENT; PROTEIN URINE LEVEL; PRURITUS; PSYCHOMOTOR DISORDER; RASH; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TREATMENT DURATION; URTICARIA; VASCULAR ACCESS; VOMITING; WHEEZING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DATABASES, FACTUAL; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HUMANS; IDURONATE SULFATASE; INFANT; INFUSIONS, INTRAVENOUS; MUCOPOLYSACCHARIDOSIS II; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951576876     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318206786f     Document Type: Article

References (20)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3421-3452.
2. Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA 1973;70:2134-2138.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254. (Pubitemid 29058114)
4. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121:e377-e386. (Pubitemid 351198459)
5. Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child 1982;57:828-836. (Pubitemid 13238787)
6. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983;25:481-489. (Pubitemid 13030892)
7. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey (HOS). Genet Med 2008;10:508-516.
8. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473.
9. Muenzer J, Gucsavas-Calikoglu M, McCandless S, Schuetz T, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007;90:329-337. (Pubitemid 46241902)
10. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;1-190.
11. Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet 1982;19:408-411. (Pubitemid 13167537)
12. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-354. (Pubitemid 43159987)
13. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749. (Pubitemid 32525371)
14. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human a-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16. (Pubitemid 32634266)
15. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. JPediatr 2006;148:533-539.
16. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144:581-588. (Pubitemid 38594757)
17. Benichou B, Goyal S, Sung C, Norfleet AM, O'Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009;96:4-12.
18. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab 2010;99:18-25.
19. Little C, Gould R, Hendriksz C. The management of children with Hunter syndrome-a case study. Br J Nursing 2009;18:321-322.
20. Galan-Gomez E, Guerrero-Rico A, Caceres-Marzal C, et al. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome. Eur J Med Genet 2008;51:268-271.